These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22852805)

  • 1. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S; Cesaretti J; Stone NN; Stock RG
    BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
    Lee WR; McQuellon RP; Case LD; deGuzman AF; McCullough DL
    J Urol; 1999 Aug; 162(2):403-6. PubMed ID: 10411047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life after radical retropubic prostatectomy and permanent prostate brachytherapy: a 3-year follow-up study.
    Hashine K; Yuasa A; Shinomori K; Ninomiya I; Kataoka M; Yamashita N
    Int J Urol; 2011 Dec; 18(12):813-9. PubMed ID: 21995507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.
    Blaivas JG; Weiss JP; Jones M
    BJU Int; 2006 Dec; 98(6):1233-7; discussion 1237. PubMed ID: 17125481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
    Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
    Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of health-related quality of life in patients with prostate cancer after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy.
    Dragićević S
    Urol Int; 2010; 85(2):173-9. PubMed ID: 20606405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term urinary sequelae following 125iodine prostate brachytherapy.
    Crook J; Fleshner N; Roberts C; Pond G
    J Urol; 2008 Jan; 179(1):141-5; discussion 146. PubMed ID: 17997424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.
    Pinkawa M; Fischedick K; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Urology; 2006 Jul; 68(1):104-9. PubMed ID: 16806434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
    BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma.
    Wehle MJ; Lisson SW; Buskirk SJ; Broderick GA; Young PR; Igel TC
    Mayo Clin Proc; 2004 Mar; 79(3):314-7. PubMed ID: 15008604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy-related dysuria.
    Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Lief JH
    BJU Int; 2005 Mar; 95(4):597-602. PubMed ID: 15705087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.